<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979965</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-0173</org_study_id>
    <nct_id>NCT01979965</nct_id>
  </id_info>
  <brief_title>Effect of Ranolazine on Valvular Disease in Patients With Pacemakers</brief_title>
  <acronym>REIN-MR</acronym>
  <official_title>Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Cardiology</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether mitral regurgitation (or a leaky heart
      valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve
      after administration of ranolazine.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>effective regurgitant orifice by echocardiography</measure>
    <time_frame>Day T = 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>proximal isovelocity surface area by echocardiography</measure>
    <time_frame>T = 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire</measure>
    <time_frame>T = 0 days, and T = 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rose Dyspnea Scale</measure>
    <time_frame>T = 0 days, and T= 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>T = 90 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ischemic Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine therapy for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill therapy for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine (Active drug)</intervention_name>
    <description>Ranolazine therapy for three months</description>
    <arm_group_label>Active drug</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo therapy for three months</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic cardiomyopathy AND

          -  Moderate or severe mitral regurgitation AND

          -  Cardiac resynchronization therapy (CRT) ≥ 3 months prior to enrollment AND

          -  Maximal Medical Therapy (ACE-Inhibitor, beta blocker, aldosterone antagonist,
             diuretic, aspirin, statin)

        Exclusion Criteria:

          -  nonischemic cardiomyopathy

          -  active heart failure

          -  current ranolazine therapy

          -  congenital heart disease

          -  mechanical valve prostheses

          -  vegetation/endocarditis

          -  significant pulmonary disease

          -  peripheral vascular disease

          -  trivial or mild mitral regurgitation

          -  creatinine clearance &lt; 30 mL/min

          -  liver cirrhosis

          -  strong inhibitors of CYP3A (including ketoconazole, itraconazole, clarithromycin,
             nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)

          -  strong inducers of CYP3A (including rifampin, rifapentine, phenobarbital, phenytoin,
             carbamazepine and St.John's wort)

          -  Strong P-glycoprotein inhibitors (including cyclosporine, verapamil, and quinidine)

          -  Initial QTc interval ≥ 440msec
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Baljepally, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Cardiology</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://utcardiology.com</url>
    <description>University Cardiology</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>cardiac resynchronization therapy</keyword>
  <keyword>ranolazine</keyword>
  <keyword>maximal medical therapy</keyword>
  <keyword>ischemic cardiomyopathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
